WEBVTT

00:00:00.000 --> 00:00:02.310 align:middle line:90%


00:00:02.310 --> 00:00:04.110 align:middle line:84%
BRYAN WOOD: The US Food
and Drug Administration

00:00:04.110 --> 00:00:06.360 align:middle line:84%
on Monday granted
the emergency use

00:00:06.360 --> 00:00:08.370 align:middle line:84%
of the first
experimental antibody

00:00:08.370 --> 00:00:10.590 align:middle line:90%
treatment for COVID-19.

00:00:10.590 --> 00:00:14.520 align:middle line:84%
Eli Lilly's bamlanivimab
is a monoclonal antibody,

00:00:14.520 --> 00:00:16.890 align:middle line:84%
or a synthetic
copy of an antibody

00:00:16.890 --> 00:00:20.130 align:middle line:84%
used by the immune system
to fight infection.

00:00:20.130 --> 00:00:23.340 align:middle line:84%
The US government has
purchased 300,000 doses

00:00:23.340 --> 00:00:25.620 align:middle line:84%
of the drug, which the
company said it will

00:00:25.620 --> 00:00:27.750 align:middle line:90%
begin shipping immediately.

00:00:27.750 --> 00:00:30.420 align:middle line:84%
There will be no out-of-pocket
costs for patients,

00:00:30.420 --> 00:00:33.270 align:middle line:84%
according to US officials,
although health care

00:00:33.270 --> 00:00:36.300 align:middle line:84%
facilities may charge
an administration fee.

00:00:36.300 --> 00:00:39.810 align:middle line:84%
Trial data showed that a one
time infusion of Eli Lilly's

00:00:39.810 --> 00:00:42.930 align:middle line:84%
treatment reduced the
need for hospitalization

00:00:42.930 --> 00:00:47.700 align:middle line:84%
or emergency room visits in
high risk COVID-19 patients.

00:00:47.700 --> 00:00:50.550 align:middle line:84%
US regulators have authorized
Eli Lilly's treatment

00:00:50.550 --> 00:00:53.070 align:middle line:84%
for patients who have
been recently diagnosed

00:00:53.070 --> 00:00:57.540 align:middle line:84%
with mild to moderate
COVID-19, over the age of 65,

00:00:57.540 --> 00:01:00.240 align:middle line:84%
and for patients 12
and older who have

00:01:00.240 --> 00:01:02.250 align:middle line:90%
an underlying health condition.

00:01:02.250 --> 00:01:04.920 align:middle line:84%
The treatment will not be
used on patients already

00:01:04.920 --> 00:01:08.520 align:middle line:84%
hospitalized or who
require oxygen therapy,

00:01:08.520 --> 00:01:11.100 align:middle line:84%
as a US
government-sponsored study

00:01:11.100 --> 00:01:13.500 align:middle line:84%
found it could worsen
the clinical outcome

00:01:13.500 --> 00:01:15.390 align:middle line:90%
in these cases.

00:01:15.390 --> 00:01:18.270 align:middle line:84%
In an emailed statement, the
White House hailed the FDA's

00:01:18.270 --> 00:01:21.030 align:middle line:90%
decision as a major milestone.

00:01:21.030 --> 00:01:24.120 align:middle line:84%
US President Donald Trump
received a similar treatment

00:01:24.120 --> 00:01:26.430 align:middle line:84%
created by Regeneron
after he was

00:01:26.430 --> 00:01:29.550 align:middle line:84%
diagnosed with the
coronavirus in early October.

00:01:29.550 --> 00:01:31.770 align:middle line:84%
Regeneron is currently
seeking emergency

00:01:31.770 --> 00:01:36.150 align:middle line:84%
approval for a dual antibody
treatment against COVID-19.

00:01:36.150 --> 00:01:40.020 align:middle line:84%
Meanwhile, Eli Lilly
anticipates manufacturing up

00:01:40.020 --> 00:01:43.020 align:middle line:84%
to 1 million doses
of bamlanivimab

00:01:43.020 --> 00:01:46.860 align:middle line:84%
by the end of 2020 for
use around the world

00:01:46.860 --> 00:01:49.200 align:middle line:90%
through early next year.

00:01:49.200 --> 00:01:50.000 align:middle line:90%